Skip to main content
Equibles
KARD logo

KARD · Kardigan, Inc.

Track KARD — free

Use KARD with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$20.74 -1.18 (-5.38%) At close · Sep 3
Rebalance outlook locked
Going-concern doubt — cleared Aug 11, 2026

The latest filing states the doubt was alleviated.

“The Company previously concluded that recurring losses, negative cash flows from operations, and limited liquidity raised substantial doubt about its ability to continue as a going concern. In June 2026, the Company completed its IPO and received net proceeds of approximately $422.4 million. Upon closing of the IPO and receipt of the associated net proceeds, the Company alleviated the substantial doubt that previously existed.”
View the 10-Q filed Aug 11, 2026
Market Cap
$1.95B
Shares
93.50M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$20.74 Open$21.96 Day$20.41–22.22 Available close range$19.60–25.90 Avg vol 30d226K Short int1.9M · 2.1% float · 9.3d Short vol57% DataJun 2026–Sep 2026 Filing10-Q · Aug 11

The closing range uses available history since Jun 18, 2026; less than a full year is stored.

Up next

Latest filing: 10-Q
filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$384.00M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+103.5%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
2.1%
Latest settlement · 9.3 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Limited Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.47
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 50-day avg −4%
below
RSI (14) 49
neutral
MACD trend Positive
52-week position 18%
mid-range
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+68 funds added
Insider flow Accumulating
Net +$90.0M over 90 days · 0% sells
Short interest Rising
2.07% of float · ▲ +22.6% MoM · 9.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
68 holders — 13F breadth
Squeeze score 62
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 70%
annualized · 1-yr
Max drawdown −24%
past year
ATR 7.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−4% Neutral
RSI (14)
49 Neutral
MACD trend
Positive Bullish
52-week position
18% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+68 funds added
Insider flow Accumulating
Net +$90.0M over 90 days · 0% sells
Short interest Rising
2.07% of float · ▲ +22.6% MoM · 9.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
68 holders — 13F breadth
Price context
position in its available closing range
Range low $20 Now $21 · 18% Range high $26
vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
KARD
Kardigan, Inc.
this stock
$1.95B — — — 2.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $140.51B +23.1% +46.2% 32.3 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $86.84B +9.3% +20.8% 20.9 2.3%
ARGX
Argenx SE
 $65.63B +25.3% — — 1.9%
CSLLY
Csl Ltd
 $59.96B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
68
% held
61.2%
Net QoQ
+57.2M sh
Top holder
HRTG GPE, LLC
Held Float
View
Held by Funds
Fund positions
40
View
Short & Settlement
Short Interest Rising
Shares short
1.9M
Days to cover
9.3d
Change
+356.9K sh
View
Short Volume
Short vol %
57%
As of
Sep 3, 2026
Short Total
View
Fails to Deliver
FTD shares
19.7K
Value
$435.3K
As of
Aug 12, 2026
View
Off-Exchange
Off-exchange %
36.7%
Week of
Jul 27, 2026
Off-exch Lit
View
Smart Money
Insider Trades Cluster buy
Net (90d)
+$90.0M
Buyers / Sellers
3 / 0
Buyers Sellers
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 11, 2026
This year
3
View

Performance

5D 20D 120D MTD YTD
KARD -0.3% +1.9% — +2.9% —
SPY +0.3% +0.6% +16.7% +0.8% +13.4%
vs SPY -0.6% +1.3% — +2.1% —
Key facts CIK 2123613 CUSIP 485925101 13F (30d) 65 filings 63 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)